Clinical and therapeutical management of gastrointestinal stromal tumours (GIST);Tratamiento de los tumores de la estroma gastrointestinal (GIST)

Medicina Clinica

Volumn 127, Issue 17, 2006, Pages 660-668

  Gómez Senent, Silvia ^a   Raposo, César Gómez ^a   Cabral, José María Segura ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; DIFFERENTIAL DIAGNOSIS; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOBLASTOMA; LEIOMYOMA; LEIOMYOSARCOMA; PROGNOSIS; PROTO ONCOGENE;

EID: 33845456145     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13094822     Document Type: Review

References (101)

1. Mazur MT, Clark HB. Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol. 1983;7:507-19.
2. Kindblom LG, Remoti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the intersticial cell of Cajal. Am J Pathol. 1998;152:1259-69.
3. Miettinen M, Virolainen M, Sarlomo-Rikala M. Gastrointestinal stromal tumors: value of CD34 antigen in their identification and separation from true leiomyomas and schawannomas. Am J Surg Pathol. 1995;19:207-17.
4. Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol. 1999;23:377-89.
5. Robinson TL, Sircar K, Hewlett BR, Chorneyko K, Riddell RH, Huizinga JD, et al. Gastrointestinal stromal tumors may originate from a subset of CD34-positive intersticial cells of Cajal. Am J Pathol. 2000;156:1157-63.
6. Poveda A, Maurel J, Martín J, Artigas V, Casado A, Cervera J, et al. Guía de práctica clínica en los tumores estromales gastrointestinales. Cir Esp. 2005;78 Supl 2:1-13.
7. Miettinen M, Lasota J. Gastrointestinal stromal tumors. Definition, clinical, histological, inmunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1-12.
8. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs); a review. Eur J Cancer 2002;38:S39-S51.
9. Rossi CR, Mocellin S, Mencarelli R, Foletto M, Pilati P, Nitti D, et al. Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer. 2003;107:171-6.
10. Bucher P, Villiger P, Egger JF, Bubler L, Morel P. Management of gastrointestinal stromal tumours: from diagnosis to treatment. Swiss Med Wkly. 2004;134:145-53.
11. Heinrich MC, Rubin BP, Longley Bj, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol. 2002;33:484-95.
12. Asman LK. The biology of stem cell factor and its receptor c-kit. Int J Biochem Cell Biol. 1999;31:1037-51.
13. Broudy VC. Stem cell factor and hemotopoiesis. Blood. 1997;90:1345-64.
14. Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, Fukuda T. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma, and seminoma/dysgerminoma in human: inmunohistochemical study of formalin-fixed, paraffin-embedded tissues. Virchows Arch. 1994;424:135-41.
15. Sanders KM. A case for interstitial cells of Cajal as pacemekers and mediators of neurotransmission in the gastrointestinal tract. Gastroenterology. 1996;111:492-515.
16. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-80.
17. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001;61:8118-21.
18. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol. 1999;154:53-60.
19. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal tumors. J Clin Oncol. 2004;22:3813-25.
20. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-10.
21. Miettinen M, Sobin LH, Sarlomo-Rikala M. Inmunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol. 2000;13:1134-42.
22. Wang L, Vargas H, French SW. Cellular origin of gastrointestinal stromal tumors: A study of 27 cases. Arch Pathol Lab Med. 2000;124:1471-5.
23. Graadt van Roggen JF, Van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis. J Clin Pathol. 2001;54:96-102.
24. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumours. Ann Chir Gynaecol. 1998;87:278-81.
25. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumours: recent advances in understanding of their biology. Hum Pathol. 1999;30:1213-20.
26. Ludwig DJ, Traverso LW. Gut stromal tumours and their clinical behavior. Am J Surg. 1997;173:390-4.
27. Shiu MH, Farr GH, Papachristou DN, Hajdu SI. Myosarcomas of the stomach: natural history, prognostic factors and management. Cancer. 1982;49:177-87.
28. Davis GB, Blanchard DK, Hatch GF, Wertheimer-Hatch L, Hatch K, Foster RS, et al. Tumors of the stomach. World J Surg. 2000;24:412-20.
29. Ruiz AR, Nassar AJ, Fromm H. Multiple malignant gastric stromal tumors presenting with GI bleeding: a case report and a review of the literature. Gastrointest Endosc. 2000;51:225-8.
30. Akwari OE, Dozois RR, Weiland LH, Beahrs OH. Leiomyosarcoma of the small and large bowel. Cancer. 1978;42:1375-84.
31. Blanchard DK, Budde JM, Hatch GF, Wertheimer-Hatch L, Hatch KF, Davis GB, et al. Tumors of the smal intestine. World J Surg. 2000;24:421-9.
32. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon. A clinicopathologic, inmunohistochemical and molecular genetic study of 44 cases. Am J Surg Pathol. 2000;24:1339-52.
33. Miettinen M, Sarlomo-Rikala M, Sobin L, Lasota J. Esophageal stromal tumors: a clinicopathologjc, inmunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol. 2000;24:211-22.
34. Hatch GF, Wetheimer-Hatch L, Hatch KF, Davis GB, Blanchard DK, Foster RS, et al. Tumors of the esophagus. World J Surg. 2000;24:401-11.
35. Miettinen M, Monihan JM, Sarlomo-Rikala M, Kovatich AJ, Carr NJ, Emory TS, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol. 1999;23:1109-18.
36. Lin SC, Huang MJ, Zeng CY, Wang TI, Liu ZL, Shiay RK, et al. Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors. Worl J Gastroenterol. 2003;9:2809-12.
37. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Lonley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-65.
38. Hirata S, Ohashi A, Nishida T, Isazaki K, Kinoshita K, Shinomura Y, et al. Gain-of function mutations of platelet-derives growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003;125:660-7.
39. Rubin BP, Fletcher JA, Fletcher CD. Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors. Int J Surg Pathol. 2000;8:5-10.
40. Blay P, Astudillo A, Buesa JM, Campo E, Abad M, García- García J, et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res. 2004;10:4089-95.
41. Duensing A, Joseph NE, Medeiros F, Smith F, Hornick JL, Heinrich MC, et al. Protein kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res. 2004;64:5127-31.
42. Tsujimura T, Makiishi-Shimobayashi C, Lundkvist J, Lendahl U, Nakasho K, Sugihara A, et al. Expression of the inmediate filament nestin in gastrointestinal stromal tumors and interstitial cells of Cajal. Am J Pathol. 2001;158:817-23.
43. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165:107-13.
44. Shidham VB, Chivukula M, Gupta D, Rao RN, Komorowski R. Inmonohistochemical comparison of gastrointestinal stromal tumor and solitary fibrous tumor. Arch Pathol Lab Med. 2002;126:1189-92.
45. Pylkkanen L, Sarlomo-Rikala M, Wessman M, Hamalainenen E, Sainio M, Husgafvel-Pursiainen K, et al. Chromosome 22q alterations and expression of the NF2 gene product, merlin, in gastrointestinal stromal tumors. Hum Pathol. 2003;34:872-9.
46. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004;28:889-94.
47. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer. 2002;38:S37-S8.
48. Saund MS, Demetri GD, Ashley SW. Gastrointestinal stromal tumors (GISTs). Curr Opin Gastroenterol. 2004;20:89-94.
49. Lau S, Tam KF, Kam CK, Lui CY, Siu CW, Lam HS, et al. Imaging of gastrointestinal stromal tumors (GIST). Clin Radiol. 2004;59:487-98.
50. Chak A, Canto MI, Rosch T, Dittler HJ, Hawes RH, Tio TL, et al. Endosonographic differentiation of benign and malignant stromal cell tumors. Gastrointest Endosc. 1997;45:468-73.
51. Hunt GC, Smith PP, Faigel DO. Yield of tissue sampling for submucosal lesions evaluated by endoscopic ultrasound. Gastrointest Endosc. 2003;57:68-72.
52. Waxman I, Saitoh Y, Raju GS, Watari J, Yokota K, Reeves AL, et al. High-frequency probe EUS-assisted endoscopic mucosal resection: a therapeutic strategy for submucosal tumors of the GI tract. Gastrointest Endosc. 2002;55:44-9.
53. Davila R, Faigel D. Gastrointestinal stromal tumors. Gastrointest Endosc. 2003;58:80-8.
54. Caletti G, Zani L, Bolondi L, Brocchi E, Rollo V, Barbara L. Endoscopic ultrasonography in the diagnosis of gastric submucosal tumor. Gastrointest Endosc. 1989;35:413-8.
55. Boyce GA, Sivak MV Jr, Rosch T, Classin M, Fleischer DE, Boyce HW, et al. Evaluation of submucosal upper gastrointestinal tract lesions by endoscopic ultrasound. Gastrointest Endosc. 1991;37:449-54.
56. Tio TL, Tytgat GN, Den Hartog Jager FC. Endoscopic ultrasonography for the evaluation of smooth muscle tumors in the upper gastrointestinal tract: an experience with 42 cases. Gastrointest Endosc. 1990;36:342-50.
57. Kameyama H, Niwa Y, Arisawa T, Goto H, Hayakawa T. Endoscopic ultrasonography in the diagnosis of submucosal lesions of the large intestine. Gastrointest Endosc. 1997;46:406-11.
58. Gu M, Ghafari S, Nguyen PT, Lin F. Cytologic diagnosis of gastrointestinal stromal tumors of the stomach by endoscopic ultrasound-guided fine-needle aspiration biopsy. Cytomorphologic and inmunohistochemical study of 12 cases. Diagn Cytopathol. 2001;25:343-50.
59. Rader AE, Avery A, Wat CL, McGreevey LS, Faigel D, Heinrich MC. Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, inmunocytochemistry, and mutational analysis of c-kit. Cancer Cytopathol. 2001;93:269-75.
60. Ando N, Goto H, Niwa Y, Hirooka Y, Ohmiya N, Nagasaka T, et al. The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with inmunohistochemical analysis. Gastrointest Endosc. 2002;55:37-43.
61. Demetri GD, Benjamin R, Blanke CD. Optimal management of patients with gastrointestinal stromal tumors (GIST). Expansion and update of NCCN Clinical Practice Guidelines. JNCCN. 2004;2 Suppl 1:1-26.
62. Hasegawa S, Semelka RC, Noone TC, Woosley JT, Marcos HB, Kenney PJ, et al. Gastric stromal sarcomas correlation of MR imaging and histopatologic findings in nine patients. Radiology. 1998;208:591-5.
63. Choi H, Charnsangavej C, De Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004;183:1619-28.
64. 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17-21.
65. Kristensen CA. FDG-PET versus spiral CT for evaluation of STI-571 treatment of gastrointestinal stromal tumors [resumen 3311]. ASCO; 2003.
66. Benjamin RS, Choi H, Charnsangavej CH. We should desist using RECIST, at least in GIST [resumen 195]. 9th Annual Meeting of the Connective Tissue Oncology Society. American Society of Clinical Oncology (CASCO). Chicago May 31-June 3, 2003. 2003;6-8:40.
67. Demetri GD, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;22:472-80.
68. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of March 20-21st 2004, under the auspices of ESMO. Ann Oncol. 2005;16:566-78.
69. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumors. Lancet Oncol. 2002;3:655-64.
70. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002;38 Suppl 5:60-5.
71. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach. A clinicopathologic, inmunohistochemical, and molecular genetic study of 1765 cases with Ing-term follow up. Am J Surg Pathol. 2005;29:52-68.
72. Bucher P, Taylor S, Villiger P, Morel P, Brundler MA. Are there any prognostic factors for small intestinal stromal tumors? Am J Surg. 2004;187:761-6.
73. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Anderson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-6.
74. Kindblom L-G, Meis-Kindblom J, Bumming P. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST)-a population-based study of 600 cases. Ann Oncol. 2002;13 Suppl 5:157.
75. Noguchi T, Sato T, Takeno S, Uchida Y, Kashima K, Yokoyama S, et al. Biological analysis of gastrointestinal stromal tumors. Oncol Rep. 2002;9:1277-82.
76. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002;20:3898-905.
77. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 1999;59:4297-300.
78. Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff E, et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer. 2003;106:887-95.
79. Chen MYM, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GIST) treated with Gleevec (imatinib mesylate). AJR Am J Roentgenol. 2002;179:1059-62.
80. Carson W, Karakousis C, Douglass H, Rao U, Palmer ML. Results of an aggressive treatment of gastric sarcoma. Ann Surg Oncol. 1994;1:244-51.
81. Roberts P, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer. 2002;38 Suppl 5:537-8.
82. Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal stromal tumors. Current Treat Options Oncol. 2001;6:1-5.
83. Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol. 2001;8:50-9.
84. Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg. 2003;90:332-9.
85. Besana-Ciani I, Boni L, Dionigi G, Benevento A, Dionigi R. Outcome and long term results of surgical resection for gastrointestinal stromal tumors (GIST). Scand J Surg. 2003;92:195-9.
86. Miettinen M, El-Rifai W, Sobin L, Lasota J, Trupiano JK, Stewart RE, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002;33:478-83.
87. Rossi CR, Mocellin S, Mencarelli R, Foletto M, Pilati P, Nitti D, et al. Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer. 2003;107:171-6.
88. Demetri G. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with selective inhibitor mesylate (STI571). Eur J Cancer. 2002;38 Suppl 5:52-5.
89. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-8.
90. Van Oosterom AT, Judson IR, Verweij J, Stroobants S, Di Paola ED, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358:1421-3.
91. Van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donate di Paola E, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002;38 Suppl 5:83-7.
92. Benjamin RS. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: intergroup S0033 early results. Proc Ann Meet Am Assoc Clin Oncol. 2003;22:A3271.
93. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomised trial. Lancet. 2004;364:1127-34.
94. Rankin C, Von Mehren M, Blanke C. Dose effect of imatinib in patients with metastasic GIST.Phase III Sarcoma Group Study 50033. [resumen 2005]. Proc Ann Meet Am Soc Clin Oncol. 2004;22 (14 Suppl):A9005.
95. Blay JY, Berthaud P, Perol D. Continuous vs intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French Sarcoma Group. Proc Ann Meet Am Soc Clin Oncol. 2004;23:815.
96. Judson I, Ma P, Peng B, Verweij J, Racine A, Di Paola ED, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005;55:379-86.
97. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointtestinal stromal tumors entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004;40:689-95.
98. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology. 2004;127:294-9.
99. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005;128:270-9.
100. Demetri GD, Van Oosterom AT, Blackstein M, Garrett C, Shah M, Heinrich M, et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST [resumen 4000]. J Clin Oncol. 2005;23:308S.
101. Benjamin RS, Blanke CD, Blay JY, Bonvalot S, Eisenberg B. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. Oncologist. 2006;11:9-20.